- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02073448
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
February 27, 2017 updated by: Galderma R&D
A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12 weeks, in the Japanese patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
417
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kagoshima, Japan
- Galderma Investigational Site
-
Osaka, Japan
- Galderma Investigational Site
-
Saitama, Japan
- Galderma Investigational Site
-
-
Hokkaido
-
Chitose, Hokkaido, Japan
- Galderma Investigational Site
-
Kitami, Hokkaido, Japan
- Galderma Investigational Site
-
Sapporo, Hokkaido, Japan
- Galderma Investigational Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan
- Galderma Investigational Site
-
-
Okayama
-
Kurashiki, Okayama, Japan
- Galderma Investigational Site
-
-
Osaka
-
Daito, Osaka, Japan
- Galderma Investigational Site
-
Neyagawa, Osaka, Japan
- Galderma Investigational Site
-
Sakai, Osaka, Japan
- Galderma Investigational Site
-
-
Tokyo
-
Adachi, Tokyo, Japan
- Galderma Investigational Site
-
Setagaya, Tokyo, Japan
- Galderma Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women at the age of 12 or older at the Screening visit.
- Those with clinical diagnosis of acne vulgaris with more than 20 noninflammatory lesions (open and closed comedones) and 12 to 100 (inclusive) inflammatory lesions (papules, pustules and nodules) on the face (forehead, both cheeks, nose and chin).
Exclusion Criteria:
- Those with more than two nodular acne lesions or any cysts.
- Those with the diagnosis of any acne conglobata, any acne fulminans, any chloracne, or any drug induced acne.
- Those who have clinically significant abnormal findings or conditions on skin other than acne such as atopic dermatitis, perioral dermatitis, or rosacea that potentially interfere with study assessments according to Investigator's judgment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GK530G
Fixed-dose combination gel of Adapalene and Benzoyl Peroxide
|
Other Names:
|
Active Comparator: CD0271
Adapalene 01% Gel
|
Other Names:
|
Active Comparator: CD1579
Benzoyl Peroxide 2.5% Gel
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent Changes From Baseline in Total Lesion Counts
Time Frame: Baseline - Week12
|
Baseline - Week12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Subjects With Adverse Events
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
Local Tolerability (Erythema)
Time Frame: 12 weeks
|
Highest severity of local tolerability scores worse than Baseline
|
12 weeks
|
Local Tolerability (Scaling)
Time Frame: 12 weeks
|
Highest severity of local tolerability scores worse than Baseline
|
12 weeks
|
Local Tolerability (Dryness)
Time Frame: 12 weeks
|
Highest severity of local tolerability scores worse than Baseline
|
12 weeks
|
Local Tolerability (Pruritus)
Time Frame: 12 weeks
|
Highest severity of local tolerability scores worse than Baseline
|
12 weeks
|
Local Tolerability (Stinging/Burning)
Time Frame: 12 weeks
|
Highest severity of local tolerability scores worse than Baseline
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
October 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
February 20, 2014
First Submitted That Met QC Criteria
February 25, 2014
First Posted (Estimate)
February 27, 2014
Study Record Updates
Last Update Posted (Actual)
March 28, 2017
Last Update Submitted That Met QC Criteria
February 27, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Acneiform Eruptions
- Sebaceous Gland Diseases
- Acne Vulgaris
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Dermatologic Agents
- Benzoyl Peroxide
- Adapalene
Other Study ID Numbers
- RDT.07.SPR.27123
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
Clinical Trials on GK530G
-
Galderma R&DCompleted